Plavix can help your heart
As researchers say, an enormous progress can be achieved in the treatment of heart diseases using a heart remedy Plavix, in combination with aspirin.
The studies show that this combination of medicines may increase the chances of survival of patients with severe heart disease by 30%. Both Aspirin and Plavix, also known as clopidogrel, have long been used in the treatment of patients suffering from heart diseases, but when used concomitantly their effectiveness is increased.
In 2006, the FDA approved Plavix, an antiplatelet medicine, for reduction of the overall mortality and frequency of a complex outcomes (recurrent heart attack, stroke, or death) in patients with acute myocardial infarction with elevated ST-segment (STEMI).
"Previously it was shown that taking clopidogrel (Plavix) with aspirin reduces the risk of recurrent myocardial infarction or stroke in patients with unstable angina or less severe heart attacks", said Dr. Mark Sabatine, the TIMI research team (Brigham and Women's Hospital). "Now, on the basis of positive results of two clinical trials, COMMIT and CLARITY-TIMI 28, clopidogrel is approved by the FDA for use in conjunction with aspirin in patients with the most serious type of heart attack, which extends the benefits of clopidogrel in patients with the whole spectrum of acute coronary syndromes".
The FDA approval was based on the results of two clinical trials which involved more than 48,000 patients with STEMI, receiving Plavix with aspirin and standard therapy, compared with patients with STEMI, who received a placebo, aspirin and standard therapy. In the study COMMIT/CCS-2 (Clopidogrel and Metoprolol in Myocardial Infarction Trial) conducted in China, the patients were observed for up to 28 days, while in the multinational study CLARITY - TIMI 28 (Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis In Myocardial Infarction Study 28), the patients were observed for 30 days.
The COMMIT/CCS-2 results have shown that during 28 days after randomization, the administration of Plavix with aspiring and standard therapy reduced the relative risk of death in patients with STEMI by 7% and reduced the relative risk of the combined event (myocardial infarction, stroke or death) by 9%.
In the study CLARITY - TIMI 28 clopidogrel along with aspirin and other standard therapy, including thrombolytics, significantly reduced the risk of occlusion of the infraction-related artery in patients with STEMI or repeated heart attack or death by 36% by the 8th day of hospitalization or the day of release.
"According to available data, every year 300,000 Americans suffer from STEMI, and those who remained alive after this, have a high risk of a recurrent atherothrombotic event", said Dr. Sabatine. "The studies COMMIT and CLARITY-TIMI 28 represent a big step forward for patients who suffered a severe heart attack, and this indication for clopidogrel (Plavix) provides clinicians with a new opportunity for patients with STEMI to reduce the risk of another heart attack, stroke or death."
In both studies, the frequency of major bleeding and intracranial hemorrhage were similar in groups of Plavix and placebo.